NHI to reimburse additional indication of Aricept.

Published: 2006-02-13 06:59:00

Updated: 2006-02-13 06:59:00

The NHI reimbursement for Aricept, an Eisai Korea drug in an additional indication of vascular schizophrenia to Alzheimer disease has been approved according to the revised ordinance dated on Jan. 31 titled "Standards for NHI payment and its detailed particulars for the methods"

According to ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK